Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
about
Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade gliomaAngiogenic inhibition in high-grade gliomas: past, present and future.Imaging biomarkers for antiangiogenic therapy in malignant gliomas.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.Assessment of therapeutic response and treatment planning for brain tumors using metabolic and physiological MRI.The Role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standardT(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients.Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.Relative percentage signal intensity recovery of perfusion metrics—an efficient tool for differentiating grades of glioma.An Update on the Approach to the Imaging of Brain Tumors.Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme.Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader StudyComparison of DSC-MRI post-processing techniques in predicting microvascular histopathology in patients newly diagnosed with GBMApplications of imaging technology in radiation research.Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century.Investigating tumor perfusion by hyperpolarized 13 C MRI with comparison to conventional gadolinium contrast-enhanced MRI and pathology in orthotopic human GBM xenografts.Arterial spin-labeling perfusion MRI stratifies progression-free survival and correlates with epidermal growth factor receptor status in glioblastoma.Early biomarkers from dynamic contrast-enhanced magnetic resonance imaging to predict the response to antiangiogenic therapy in high-grade gliomas.Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.Prognostic paradox: brain damage around the glioblastoma resection cavity.Relationship of In Vivo MR Parameters to Histopathological and Molecular Characteristics of Newly Diagnosed, Nonenhancing Lower-Grade Gliomas.
P2860
Q26826862-6FA548EA-4163-4B22-8B6A-4405D5A80582Q30455596-13E06D69-0A61-4FDD-98E7-C29B76C0C40FQ30764736-7F40C8FB-E750-45F9-AF44-2B188078E3C8Q30907831-28918E00-9D3F-4D87-A098-FFB286EB72D5Q33616649-08DD3DF0-8FB7-45A9-A2E8-AAB540B294FEQ33888366-A4D4D199-1F70-450F-8BD5-742CB9DC375BQ35090720-10D463E4-06C2-42AC-B076-0F91A646C60BQ35524040-81F1BFD4-3DE1-4E35-9D5F-B2B60B562F85Q35895174-58AA2697-9AC4-48D3-8E19-FB175AF597F2Q36295701-079A5FB3-297D-4586-B2A1-B4094047AD85Q36374577-D975725C-A12E-4BF8-A72D-6AE8A9EAB102Q36459981-57B40345-CC23-4A40-AB4A-46EB3ADF476FQ36713503-772F1412-E119-40B1-A958-56E2B3A2F0C7Q36943903-1B7D3C70-B8F5-4EF2-8CA1-1D268D9FCB8DQ36943907-5A5B2235-48D8-4D93-80B8-8A2CDC5293ECQ37014722-F7D50A48-9C4E-4262-8537-9A72199B3FF4Q37991769-4D009C28-5872-4309-AEDD-57159CE239FAQ38101368-2936874A-D455-4C13-8AF4-52B5CE4547F9Q39985970-EEFE09D4-61A2-47E5-B79A-0AACF1CFB00FQ41646607-E1E3E8CD-D3ED-45DA-8E44-70F71D6468B0Q52149377-E0FA16C5-12C8-4B08-952C-CB5707230AA0Q52151865-97186538-80D7-4CCF-B8A7-0B038FF6C074Q55461111-A7CA152D-97C0-460F-80CA-7AD173B3EEFBQ55690590-7F3BB334-0351-4C51-9648-5631CC23CA0B
P2860
Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Assessment of perfusion MRI-de ...... newly diagnosed glioblastoma.
@ast
Assessment of perfusion MRI-de ...... newly diagnosed glioblastoma.
@en
Assessment of perfusion MRI-de ...... newly diagnosed glioblastoma.
@nl
type
label
Assessment of perfusion MRI-de ...... newly diagnosed glioblastoma.
@ast
Assessment of perfusion MRI-de ...... newly diagnosed glioblastoma.
@en
Assessment of perfusion MRI-de ...... newly diagnosed glioblastoma.
@nl
prefLabel
Assessment of perfusion MRI-de ...... newly diagnosed glioblastoma.
@ast
Assessment of perfusion MRI-de ...... newly diagnosed glioblastoma.
@en
Assessment of perfusion MRI-de ...... newly diagnosed glioblastoma.
@nl
P2093
P2860
P356
P1433
P1476
Assessment of perfusion MRI-de ...... newly diagnosed glioblastoma.
@en
P2093
Emma Essock-Burns
Janine M Lupo
Mei-Yin Polley
Nicholas A Butowski
Sarah J Nelson
Soonmee Cha
Susan M Chang
P2860
P304
P356
10.1093/NEUONC/NOQ143
P577
2010-10-29T00:00:00Z